Bioregenx (BRGX) Shares Outstanding (Weighted Average) (2021 - 2026)

Bioregenx has reported Shares Outstanding (Weighted Average) for 6 years, with the latest figure at $969.2 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 1.27% year-over-year to $969.2 million; the trailing twelve-month figure through Mar 2026 stood at $969.2 million (up 1.27% YoY), and the FY2025 full-year result was $959.7 million, up 5.19% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $969.2 million, up from $959.7 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $969.2 million in Q1 2026, with the low at $3.9 million in Q1 2024.
• Average Shares Outstanding (Weighted Average) over 5 years is $666.2 million, with a median of $762.0 million recorded in 2023.
• Year-over-year, Shares Outstanding (Weighted Average) sank 99.37% in 2024 and surged 24615.76% in 2025.
• Tracing BRGX's Shares Outstanding (Weighted Average) over 5 years: stood at $269.7 million in 2022, then surged by 137.18% to $639.8 million in 2023, then soared by 42.61% to $912.4 million in 2024, then grew by 5.19% to $959.7 million in 2025, then advanced by 0.99% to $969.2 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $969.2 million (Q1 2026), $959.7 million (Q4 2025), and $959.1 million (Q3 2025), per Business Quant data.

Peer Comparison